X0306 4 2021-02-16 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001325710 Sherman Matthew L C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 0 1 0 0 EVP & Chief Medical Officer Common Stock 2021-02-16 4 S 0 132 48.87 D 37286 D Common Stock 2021-02-16 4 A 0 11100 0.00 A 48386 D Stock Option (Right to Buy) 47.79 2021-02-16 4 A 0 49900 0.00 A 2031-02-15 Common Stock 49900 49900 D This sale was to cover tax liabilities in the vesting of restricted stock. The reporting person was awarded 11,100 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 16, 2021. /s/ Jeffrey Held, Attorney-in-Fact 2021-02-18